Listed by the USPTO as MCINTOSH III, TRAVISS C
Tech Center 1600 • Art Units: 1623 1657 1673 1693
This examiner grants 73% of resolved cases
MCINTOSH III, TRAVISS C is assigned to Tech Center 1600 and art unit 1623. The record contains 1341 resolved cases, with an allowance rate of 73.3%. The median time to allowance is 886 days, combining a majority allowance outcome with a timeline that is shorter than many extended prosecution records. The volume gives the profile substantial practical weight.
The interview lift is 14.1%, associating interviews with improved allowance outcomes. Counsel may use interviews to clarify technical distinctions and focus the next written response, while recognizing that the positive association is not a guarantee for any application. The leading companies are Compass Pathfinder Limited, University of Massachusetts, and Yokogawa Electric Corporation. The leading firms are HARNESS DICKEY (DETROIT), SUGHRUE MION, PLLC, and Buchanan Ingersoll & Rooney PC.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18439034 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18744247 | KAEMPFEROL ANALOG-CONTAINING COMPOSITION | Final Rejection | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18259896 | COMPOSITION FOR CARING FOR KERTATIN MATERIALS | Final Rejection | L'OREAL |
| 18835699 | METHOD FOR PRODUCING OLIGONUCLEOTIDES | Non-Final OA | Nitto Denko Corporation |
| 18258731 | PENETRATING CRYOPROTECTION AGENTS AND METHODS OF MAKING AND USING SAME | Final Rejection | The Research Foundation for The State University of New York |
| 18720093 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OTIC INFECTIONS | Non-Final OA | Intervet Inc. |
| 18573285 | SEPARATION PROCESS | Non-Final OA | Croda International Plc |
| 18560242 | COMBINATION THERAPIES | Final Rejection | Janssen Pharmaceutica NV |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy73.3% of resolved applications examined by Traviss C Mcintosh III were allowed (1,341 resolved cases), compared with 51.3% across Art Unit 1623 over the last five years.
This examiner's interview lift is +14.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Traviss C Mcintosh III took 886 days on average from filing to allowance.
Traviss C Mcintosh III examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
